News Releases
"Although we anticipated a tough year-over-year comparison, delays in closing a number of
"Our highest priority is to remain financially healthy while demand remains soft. To that end, we have continued to make the tough decisions, aggressively reducing overhead costs and building more efficiencies into our operations, without compromising our new product development plans," added Popielec. "The gestation cycles for all of our new products are on track. Field tests are underway for our GenSet Eliminatorâ„¢ demonstration units and we are building additional units in the third quarter to keep up with the testing demands. In addition to building an opportunity funnel for these new products, we continue to advance highly attractive funded opportunities, both domestic and international, in our
Second Quarter 2012 Financial Results
As previously announced,
Revenue was
Gross profit was
Operating expenses were
Operating loss was
Net loss from continuing operations was
Outlook
For 2012, management continues to expect high-single to low-double digit year-over-year revenue growth for its Communication Systems segment and
Management cautions that the timing of orders and shipments may cause variability in quarterly results.
About
Headquartered in
This press release may contain forward-looking statements based on current expectations that involve a number of risks and uncertainties. The potential risks and uncertainties that could cause actual results to differ materially include: uncertain global economic conditions, increased competitive environment and pricing pressures, disruptions related to restructuring actions and delays. The Company cautions investors not to place undue reliance on forward-looking statements, which reflect the Company's analysis only as of today's date. The Company undertakes no obligation to publicly update forward-looking statements to reflect subsequent events or circumstances. Further information on these factors and other factors that could affect
Conference Call Information
ULTRALIFE CORPORATION | ||||||||
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME | ||||||||
(In Thousands, Except Per Share Amounts) | ||||||||
(Unaudited) | ||||||||
Three-Month Periods Ended | Six-Month Periods Ended | |||||||
July 1, | July 3, | July 1, | July 3, | |||||
2012 | 2011 | 2012 | 2011 | |||||
Revenues: | ||||||||
Battery & energy products | $ 15,523 | $ 31,239 | $ 35,605 | $ 55,487 | ||||
Communications systems | 3,183 | 11,873 | 10,602 | 15,540 | ||||
Total revenues | 18,706 | 43,112 | 46,207 | 71,027 | ||||
Cost of products sold: | ||||||||
Battery & energy products | 11,760 | 23,986 | 27,899 | 45,193 | ||||
Communications systems | 2,479 | 7,566 | 7,248 | 9,860 | ||||
Total cost of products sold | 14,239 | 31,552 | 35,147 | 55,053 | ||||
Gross profit | 4,467 | 11,560 | 11,060 | 15,974 | ||||
Operating expenses: | ||||||||
Research and development | 1,970 | 2,114 | 4,109 | 4,619 | ||||
Selling, general, and administrative | 5,429 | 6,409 | 11,172 | 12,254 | ||||
Total operating expenses | 7,399 | 8,523 | 15,281 | 16,873 | ||||
Operating income (loss) | (2,932) | 3,037 | (4,221) | (899) | ||||
Other income (expense): | ||||||||
Interest income | 2 | 1 | 3 | 2 | ||||
Interest expense | (115) | (162) | (219) | (318) | ||||
Miscellaneous | (20) | (9) | 32 | 290 | ||||
Income (loss) from continuing operations before income taxes | (3,065) | 2,867 | (4,405) | (925) | ||||
Income tax provision-current | 188 | 63 | 267 | 67 | ||||
Income tax provision (benefit)-deferred | (17) | 55 | (5) | 109 | ||||
Total income taxes | 171 | 118 | 262 | 176 | ||||
Net income (loss) from continuing operations | (3,236) | 2,749 | (4,667) | (1,101) | ||||
Discontinued operations: | ||||||||
Income (loss) from discontinued operations, net of tax | 49 | (2,325) | (22) | (4,178) | ||||
Net income (loss) | (3,187) | 424 | (4,689) | (5,279) | ||||
Net (income) loss attributable to noncontrolling interest | 20 | 15 | 20 | 28 | ||||
Net income (loss) attributable to Ultralife | $ (3,167) | $ 439 | $ (4,669) | $ (5,251) | ||||
Other comprehensive income (loss): | ||||||||
Foreign currency translation adjustments | (25) | 60 | 123 | 287 | ||||
Comprehensive income (loss) attributable to Ultralife | $ (3,192) | $ 499 | $ (4,546) | $ (4,964) | ||||
Net income (loss) attributable to Ultralife common shareholders - basic | ||||||||
Continuing operations | $ (0.18) | $ 0.16 | $ (0.27) | $ (0.06) | ||||
Discontinued operations | $ 0.00 | $ (0.13) | $ (0.00) | $ (0.24) | ||||
Total | $ (0.18) | $ 0.03 | $ (0.27) | $ (0.30) | ||||
Net income (loss) attributable to Ultralife common shareholders - diluted | ||||||||
Continuing operations | $ (0.18) | $ 0.16 | $ (0.27) | $ (0.06) | ||||
Discontinued operations | $ 0.00 | $ (0.13) | $ (0.00) | $ (0.24) | ||||
Total | $ (0.18) | $ 0.03 | $ (0.27) | $ (0.30) | ||||
Weighted average shares outstanding - basic | 17,396 | 17,296 | 17,376 | 17,286 | ||||
Weighted average shares outstanding - diluted | 17,396 | 17,308 | 17,376 | 17,286 |
ULTRALIFE CORPORATION | ||
CONSOLIDATED BALANCE SHEETS | ||
(In Thousands, Except Per Share Amounts) | ||
(unaudited) | ||
July 1, | December 31, | |
ASSETS | 2012 | 2011 |
Current assets: | ||
Cash and cash equivalents | $ 4,178 | $ 5,486 |
Trade accounts receivable, net | 15,611 | 19,903 |
Inventories | 33,692 | 34,967 |
Prepaid expenses and other current assets | 3,025 | 3,877 |
Total current assets | 56,506 | 64,233 |
Property and equipment | 12,714 | 12,588 |
Other assets: | ||
Goodwill, intangible and other assets | 23,771 | 23,994 |
Total Assets | $ 92,991 | $ 100,815 |
LIABILITIES AND SHAREHOLDERS' EQUITY | ||
Current liabilities: | ||
Short-term debt and current portion of long-term debt | $ 357 | $ -- |
Accounts payable | 10,748 | 13,766 |
Other current liabilities | 7,924 | 9,392 |
Total current liabilities | 19,029 | 23,158 |
Long-term liabilities: | ||
Other long-term liabilities | 4,517 | 4,431 |
Shareholders' equity: | ||
Ultralife equity: | ||
Common stock, par value $0.10 per share | 1,881 | 1,874 |
Capital in excess of par value | 173,087 | 172,309 |
Accumulated other comprehensive loss | (862) | (985) |
Accumulated deficit | (96,949) | (92,280) |
77,157 | 80,918 | |
Less -- Treasury stock, at cost | 7,658 | 7,658 |
Total Ultralife equity | 69,499 | 73,260 |
Noncontrolling interest | (54) | (34) |
Total shareholders' equity | 69,445 | 73,226 |
Total Liabilities and Shareholders' Equity | $ 92,991 | $ 100,815 |
CONTACT: Company Contact:Ultralife Corporation Philip Fain (315) 332-7100 pfain@ulbi.com Investor Relations Contact:Lippert/Heilshorn & Associates Jody Burfening (212) 838-3777 jburfening@lhai.com